Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab
Feb 1, 2007 | Magazine: Clinical and Translational Oncology
M. González Cao, S. Viteri, C. Garrán, Y. Nieto, J. Aristu, M. Ponz and S. Martín Algarra
We report here a taxol–bevacizumab-responsive metastatic melanoma case.
Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.
CITATION Clin Transl Oncol. 2007 Feb;9(2):119-20
Specialist Medical Oncology Department